

TECH BIZ KON

10TH
SINCE
2017

LifeTECH+ INNOVATIONS
FOR A BETTER LIFE



OCT 9 2026

YURAKUCHO // TOKYO

INNOVATION BASE



We turn science into medicine

To change the course of a disease we believe you need to advance your understanding of human and disease biology as well as listen and learn from patients to gain a deeper appreciation of their reality and needs.



Inspired by **patients.**
Driven by **science.**

**1:15 PM
- 3:15 PM**
ONSITE B2B-MEETINGS
ask infodesk at the
exhibition area for
open slots or book
via B2Match

Friday, October 9th, 2026
1:15 - 8:40pm, door: 12:45 pm
Tokyo Innovation Base
// Yurakucho // & online

TechBIZKON X
Connecting
Startups, Corpo-
rates & Investors



TECHBIZKON X

Agenda

**YOUR MC: LUCA
ESCOFFIER** Intl'
Technology Transfer
& Open Innovation
Expert // CEO //
Mugen Links // Tokyo



EVENT AGENDA

TiB 2F // STAGE

1:15 PM 1:1 Meetings Reserve your
30min slot at Tokyo In-
novation Base 1F with the
participating startups

3:25 PM LIVESTREAM Participate via
B2Match-Livestream

3:30 PM Opening Remarks
Greetings by Organizers

3:40 PM Panel Discussion
"Europe's and Japan's latest
trends in LifeTech" – host-
ed by Axel Karpenstein/
German Center for Re-
search & Innovation Tokyo

4:30 PM STARTUP Pitching I
7 pitches at 5 mins. each

5:15 PM Coffee Break

5:35 PM Startup Pitching II
8 pitches at 5 mins. each

6:20 PM Short Break

6:35 PM Startup Award Ceremony

6:50 PM Networking Cocktail
& Individual Talks
with Startups

8:40 PM Closing

TiB 1F // SQUARE 2

SPECIAL SESSION



4:00 PM Zero Project

6:30 PM Technology Forum Tokyo
Connecting highly innovative
Assistive Technology (AT) for
accessibility & disability inclusion
with potential Support Partners



LifeTECH+
INNOVATIONS FOR A BETTER LIFE



B2Match PreEvent Meetings Online on
September 28th // 29th // 30th – Online registration:
<https://www.b2match.com/e/techbizkon-x-lifetech>

TechBIZKON X
Connecting
Startups, Corporates & Investors



ON STAGE Tokyo Innovation Base 2F // Stage // + at the Tables at 1F // Square 1

STARTUP PITCHING I

16:30h	01 ANNAIDA SUI	MedTech // DeepTech 10
16:36h	02 PUXANO BE	BioTech: Vaccines // Antibodies // Membrane Proteins 11
16:42h	03 HOPETECH AT	Assistive Technology // Software // Medical Devices 12
16:48h	04 SALIVATECH JP	HealthTech // AI Cancer Screening 13
16:54h	05 EVERSIN GER	MedTech // BioTech 14
17:00h	06 REM ANALYTICS BE	MedTech // Biotech 15
17:06	07 THYRA IMAGING AT	MedTech // Medical Imaging // AI // Neuroscience // Aging & Longevity // DeepTech 16

COFFEE BREAK

17:15h	NETWORK TIME
17:35h	20 Minutes

STARTUP PITCHING II

17:35h	08 LYSANTUM BE	Regenerative medicine // Cell & Gene Therapy Supply // GMP Raw Materials 18
17:41h	09 CORROQUIUM JP	Assistive Technology // Health Tech // Wearable Devices 19
17:47h	10 ABS AT	Biotechnology 20
17:53h	11 SWIFTPHARMA BE	Biotechnology 21
17:59h	12 AORTEX GER	MedTech // Medical Devices 22
18:05h	13 SYNENDOS SUI	BioTech // Neuroscience 23
18:11h	14 CYNTERACT GER	HealthTech 24
18:17h	15 FERROPTOCURE JP	BioTech // Pharmaceutical 25

AWARD CEREMONY

18:35h	TEKBIZKON X AWARDS
18:50h	25 Minutes

AT THE TABLES Tokyo Innovation Base 1F // Square 1

EXHIBITING ONLY // NOT PITCHING

16 ALITHEA BIO GER	MedTech // FemTech // Longevity // Prvntv. Health 26
17 CHECKIMMUNE GER	MedTech // Biomarkers // Personalized Medicine 26
18 CURIO BIOTECH SUI	Medtech Device // Diagnostics 27
19 DIAMENS AT	Femtech // Diagnostics 27
20 FYONIBIO GER	Cell & Gene Therapy // Bioprocessing 27
21 IMMUNOSENS JP	MedTech // Immune Biomarkers // Wellness // Digital Health 27
22 KINCON AT	BioTech // Pharma R&D // Advanced Therapeutic 28
23 LUMINOUS LABS AT	Device // FemTech // Longevity // Wellness & Preventive Health 28

24 MAGNES CH	Rehab Device // MedTech // Wearables 28
25 NANOTIS JP	BioTech // Pharma R&D // Advanced Therapeutic 29
26 NEUROLONIC GER	Digital Health // Medical Device // Wearables 29
27 NG SCOPES GER	MedTech // MedDev. // Endoscopy // Endos. Robtcs. . 30
28 NUVONIS AT	Biotech // Pharma R&D // Food-Tech 30
29 OMICS BUDDY GER	TechBio // Bioinformatics // AI Agents // RNA-SEQ 30
30 ORGANTECH JP	Longevity & Regenerative Med. // Wellness & Preventive Health 31
31 PRIMA GNTCS. SUI	Medtech Device // Diagnostics 31

32 QFF JP	AgriTech & Deep-Tech // Wellness & Preventive Health 32
33 SNORE FREE AT	App // E-Health // Medical Device // Lifestyle 32
34 SYMIND GER	Mental // Voice AI // Stress Prevention // Wellbeing .. 32
35 THE ELEMENTS JP	MedTech & Assistive Tech // Wellness & Preventive Health 33
36 TORARU JP	Digital Health & Assistive Tech // Deep Tech & Metaverse 33



CONTENT

ORGANIZED BY



3 **EVENT AGENDA**
7 **PANEL DISCUSSION**

9 **PITCHING STARTUPS**

26 **EXHIBITING STARTUPS**


34 **TECHBIZKON HISTORY**

25 **ORGANIZERS**
36 **PARTNERS**

LifeTECH+
INNOVATIONS FOR A BETTER LIFE



ORGANIZED BY



Also streamed online:

Find further information about our panelists under "Agenda" after logging into our B2Match-site
<https://www.b2match.com/e/techbizkon-x-lifetech>

// TECHBIZKON X // LIFETECH+ INNOVATIONS FOR A BETTER LIFE // TOKYO INNOVATION BASE (TiB) // 2F // STAGE // THE PANEL DISCUSSION

Industry and technology experts from all organizing countries discuss the state of play of LifeTech+ issues in their respective markets

Panel Discussion

Oct. 9TH, 3:40 PM – 4:30 PM Japan Standard Time

Europe's & Japan's latest trends in LifeTech+

HOST: AXEL KARPENSTEIN

Director German Center for Research and Innovation (DWIH) Tokyo



Mag. **LEJLA POCK**
AUSTRIA //
Managing Director //
Human.technology Styria



RAKESH NAIR PhD
FLANDERS // Business
Development Manager
Bio Base Europe Pilot Plant



Dr. **AMINA
SUGIMOTO** DrPH
GERMANY // Founder &
CEO // Fermata Inc.



NOBUKO HIBINO PhD JAPAN
// Prof. @ Faculty of Culture
& Sport Policy, Toin Univ.
Yokohm. // Board Member JASP



SACHI INUKAI PhD
SWITZERLAND // Senior
Scientist // Chugai
Pharmaceutical



The **Global Incubator Network Austria (GIN)** is the **connecting link between Austrian and international startups, investors, incubators and accelerators** with a special focus on selected hotspots in Asia (Mainland China, Hong Kong, Singapore, Japan, South Korea and Israel). **GIN enables the internationalization of startups** by building networks, providing know-how, and connecting them with relevant players of global startup hotspots.

GIN CONNECTS | OUR SERVICES

GIN FOR AUSTRIAN STARTUPS:

With GO ASIA we bring Austrian startups to the world's most innovative startup hubs, help them to build networks with international strategic partners and provide them with essential know-how in terms of market entry and global expansion – strategically and financially.

GIN FOR ASIAN STARTUPS:

With GO AUSTRIA we support Asian startups that want to internationalize and seek to further develop their business activities in the EU-market via Austria. A hand-selected mentor supports the startup in order to find the right collaboration partners (corporates, investors, ...) and to receive valuable market insights.

GIN FOR INVESTORS:

We offer investors the internationalization of existing investments, access to international startups and new investments as well as networks with private and public co-investors.

GIN FOR INCUBATORS:

Accelerators can benefit from hosting our most promising pre-selected Austrian startups and facilitate the internationalization efforts of their startups via our GO AUSTRIA program or through one of our GIN partner incubator or accelerator.

Contact us:
office@gin-austria.com
www.gin-austria.com

BE PART OF THE GIN NETWORK

GIN is owned by the Austrian Federal Government and managed by the public agencies AWS (public promotional bank) and FFG (research promotion agency).

 German
Centre for Research
and Innovation Tokyo
(DWIH Tokyo)



Meet stakeholders from academia & industry and stay up to date about recent policy trends in science & innovation!

DWIH Tokyo is a platform for German universities, research institutions and research-based companies in Japan. With its unique network of German organizations from science, research and innovation, it holds numerous events throughout the year, connecting stakeholders from Japan and Germany.

Interested in learning more? Register here for our newsletter:
www.dwih-tokyo.org/newsletter




DWIH Tokyo is part of a global network of five German Centres for Research and Innovation. Since its establishment in 2010, it has been supported by the German Federal Foreign Office. It has been coordinated by the German Academic Exchange Service (DAAD) since 2017.

Contact:

German Centre for Research and Innovation Tokyo (DWIH Tokyo)
German Culture Center 4F, 7-5-56 Akasaka, Minato-ku, Tokyo 107-0052, Japan
info@dwih-tokyo.org

LinkedIn: DWIH Tokyo
X: @DWIH_Tokyo



Life
TECH
+ INNOVATIONS
FOR A
BETTER
LIFE


TECH
BIZ
KON



PITCHING STARTUPS

The startups on the following pages are pitching at the event and are available for talks during networking time at their exhibiting table.

Further Startups
exhibiting only:
page 26



MARCO GRISI //
CEO & FOUNDER



COMPANY
ANNAIDA Technologies

DATE OF INCORPORATION
08/2019

SECTOR
Medtech // Deeptech

WEBSITE
www.annaida.ch

SPEAKER
Marco Grisi
// CEO & Founder

CONTACT
e marco.grisi@annaida.ch

STAGE
Entering Human Clinical Trials

CURRENT TARGET RAISE
JPY 1.5 B

WANTED We are raising a JPY 1.5B Series A to complete clinical validation, secure CE Mark and FDA clearance, and prepare commercial rollout of micro-MRS-MED. We seek investors and strategic partners in medtech, fertility and deep tech to support global scale-up and market entry.

PRODUCT/SERVICE

MICROMRS-MED IS A NON-INVASIVE EMBRYO SCANNER FOR IVF.

Using patented micro-MRS technology, it measures an embryo's metabolic fingerprint directly in its culture dish, without biopsy or contact, and delivers an AI-based viability score in under 30 minutes to support embryo selection.

CORE CAPABILITIES
TECHNOLOGY & COMPETITIVE EDGE


First-in-class micro-MRS metabolic profiling at embryo scale. Patented micro-chip sensors enable direct, non-invasive measurement unavailable to imaging or genetic tests. Proprietary scoring software improves through unique datasets generated by every scan.

PERFORMANCE & TRACTION

AUC 0.94 in peer-reviewed bovine embryo development prediction; human Phase 1 data collection underway. 15+ signed clinic LOIs, 5+ sites ready to onboard, 4 micro-MRS systems sold, 11 peer-reviewed papers and JPY 2B+ raised to date.



WOUTER VAN
PUTTE // CEO



COMPANY
PUXANO BV

SECTOR
Biotech: vaccines // anti-bodies // membrane proteins

WEBSITE
www.puxano.com

DATE OF INCORPORATION
09/2020

SPEAKER
Wouter Van Putte // CEO

CONTACT
e wouter.vanputte@puxano.com



STAGE
Scale-up phase

CURRENT TARGET RAISE

WANTED

- Searching for partners for discovery platform – antigen design & membrane protein (GPCRs, ion channels) drug screening platforms.
- Next investment: 10M€

PRODUCT/SERVICE

DISCOVERY PARTNER:

- Discovery platform for antigen design
- Discovery platform to perform structure-based drug design directly with patient-derived proteins, avoiding recombinant idealisations and maximizing drug efficacy
- Antigen library for major bacterial and viral pathogens thereby leveraging structure-guided diffusion-based antigen design and cryoEM to get access to new targets

CORE CAPABILITIES
TECHNOLOGY & COMPETITIVE EDGE

- Software platform for AI-based protein design
- Protein scaffolds to stabilize and present membrane proteins and protein complexes as soluble, stable, well-expressing proteins (patented)
- cryoEM grid portfolio (patented)

PERFORMANCE & TRACTION

- Investment 1.2m€
- 2.2M€ in non-dilutive funding (competitive grants)
- Revenue > 2M€
- Technology collaborations with 5 of top 10 pharma in EU and US



Hope Tech

LAURA WISSIAK
// PRODUCT
MANAGER

COMPANY
Hope Tech
Plus GmbH

**DATE OF
INCORP.**
11/2022

SECTOR
Assistive Technology //
Software // Medical Devices

WEBSITE
www.hopetech.vision

TEAM
Brian Mwenda // CEO
Laura Wissiak // PM & Speaker

CONTACT
e laura@hopetech.vision

STAGE Seed **CURRENT TARGET RAISE** EUR 2 Mio.

WANTED Disabled Persons, Organisations or community representatives (ideally focused on blindness and low vision) // Distributors of assistive technology // Public institutions supporting persons with disabilities // Joint Venture partners // Investors

PRODUCT/SERVICE

THE WHITE CANE IS A RELIABLE COMPANION TO BLIND PEOPLE WORLDWIDE, but there are still many obstacles it misses. Sixth Sense is a wearable designed to detect obstacles in your way, while keeping you on your path. The wearable sits on your shoulders, mimicking over-ear headphones, and connects with your phone to keep your hands free while guiding you to where you want to go. The navigation app can be used for route planning, with or without the wearable.

CORE CAPABILITIES TECHNOLOGY & COMPETITIVE EDGE

Sixth Sense uses infrared and ultrasonic sensors, combining the reading for object detection reliable in all lighting conditions and for all types of surfaces. Full customization of all haptic feedback and app UI is possible, making Sixth Sense compatible with all eye conditions and suitable for deaf-blind persons as well. The hardware design is inspired by headphones, to fit with different types of garments and offer a discreet look.

PERFORMANCE & TRACTION

- Official partnership with Access Austria, the leading support organization for blind persons in Austria
- Final form of Sixth Sense hardware showcased at the Future of Fashion Show as part of London Fashion Week
- Recognized in Forbes Under 30 Europe for Social Impact in 2025, and featured in Forbes Austria magazine
- Interest from 50+ countries




SalivaTech

MAKOTO
SUNAMURA,
MD, PHD //
PRESIDENT & CEO

COMPANY
SalivaTech Co., Ltd.

DATE OF INCORP.
12/2013

SECTOR
HealthTech // AI
Cancer Screening

TEAM

- Makoto Sunamura, MD, PhD // Pres. & CEO
- Masahiro Sugimoto, PhD // Dir. & CTO // Keio Univ.
- Naruhiko Ikoma, MD // Advisor // MD Anderson Cancer Center

WEBSITE
https://salivatech.co.jp

CONTACT
Takehiro Sugawara // VP
e t.sugawara@salivatech.co.jp
m +81 80 7309 3772

STAGE Growth **CRNT.TGT.RS.** ---

WANTED

- U.S. clinical partners (cancer centers, health systems, CLIA labs) for validation studies and a CLIA-LDT launch
- distribution and insurance partners in Asia and the Global South for corporate wellness channels
- strategic and financial investors for our U.S. entry and PMDA/FDA pathway
- pharma/academic partners f. biomarker research



PRODUCT/SERVICE

SALIVACHECKER IS A NON-INVASIVE MULTI-CANCER RISK SCREENING TEST. A 2-5 min saliva sample collected at home or workplace, shipped at room temp., is analyzed by LC-MS/MS metabolomics and a proprietary AI model to report risk for pancreatic, lung, gastric, colorectal, oral and breast cancer in one test. High-risk users are guided to partner clinics and online consultation, bridging self-care and med. care.

CORE CAPABILITIES TECHNOLOGY & COMP. EDGE

Keio University spin-off; 18 peer-reviewed papers. Proprietary saliva metabolite biomarkers and stabilizing reagent for room-temperature transport. Fully automated LC-MS/MS-to-AI pipeline with central QC enables low-cost lab replication overseas. Detects signals from Stage I.

PERFORMANCE & TRACTION

110,000+ tests in Japan (approx. 50,000/yr). Partners: Nippon Life, SOMPO Group, 2,000+ companies, 500+ clinics. Winner, XTC Japan 2025. SelectUSA Investment Summit 2026 delegate; presented to ACCJ Healthcare x Digital (HxD) Committee. MOUs in Taiwan and Sri Lanka; MD Anderson advisor on board.





DR. THOMAS REXER // CO-FOUNDER



COMPANY
eversyn GmbH

WEBSITE
www.eversyn.de

SECTOR
Medtech // Biotech

DATE OF INCORPORATION
01/2024

SPEAKER
Dr. Thomas Rexer
// Co-Founder &
Managing Director

CONTACT
e info@eversyn.de
t +49 391 67 54 676

STAGE
Seed

CURRENT TARGET RAISE
JPY 1.000.000.000

WANTED
We seek strategic partners and investors in Japan: ingredient/infant-nutrition and biopharma companies for partnering, co-development and supply agreements, plus co-investors for our JPY 1B seed round to fund scale-up, market entry, and team growth.

PRODUCT/SERVICE

EVERSYN ENGINEERS SUGAR-BASED TECHNOLOGIES that make biopharmaceuticals more potent and nutritional proteins gentler on the body. Glycoengineering can raise an antibody's cancer-fighting activity up to 50% at the same dose. In nutrition, we boost digestibility, cut allergenicity, and develop ingredients for healthy ageing. We seek pharma, nutrition partners and investors.

TABLE NUMBER
05
PITCH TIME
16:54-16:59 h

CORE CAPABILITIES
TECHNOLOGY & COMPETITIVE EDGE

- Spin-off from the Max Planck Society in Germany
- Proprietary technology platform producing complex glycans
- Strong IP portfolio

PERFORMANCE & TRACTION

- Seed round: €1.6M raised (approx. ¥297M)
- Government grants: €1.7M+ secured (approx. ¥316M)
- Global traction: 30+ customers worldwide
- Validation: Proof-of-concept study completed with a major Japanese corporation




PAULO REFINETTI
// CEO &
CO-FOUNDER

COMPANY
REM Analytics SA

DATE OF INCORPORATION
04/2020

SECTOR
Biotech // In vitro diagnostics
// AI-led biomarker discovery

WEBSITE
www.remanalytics.ch

SPEAKER
Paulo Refinetti // CEO & Co-Fndr.

TEKBIZKON
06
PITCH TIME
17:00-17:05 h

CONTACT
e paulo.refinetti@remanalytics.ch
m +41 76 222 0795

PRODUCT/SERVICE

A FULLY INTEGRATED, AI-LED BIOMARKER DISCOVERY PLATFORM. We take a biomarker the whole way: computational discovery, assay development, analytical and clinical validation, scale-up on our own 96-capillary instrument, and registration. Available as co-development on your targets, testing in our Swiss laboratory, or an instrument and method installed in your lab. Proven end to end: our vaginal microbiome panel is a CE-marked IVD, on sale now.

CORE CAPABILITIES
TECHNOLOGY & COMP. EDGE

ATGC: targeted DNA assays read by Cycling Temperature Capillary Electrophoresis, which separates DNA fragments of identical length differing by a single nucleotide. Species, subspecies and strain resolution; replicate variation below 1.5%. Discovery, instrument and registration in-house.

PERFORMANCE & TRACTION

CE-marked IVD on the market through YONI Solutions; a second panel sells as BifidoZoom. Assay revenue since 2020; own instrument manufactured since 2024. ~6% mean absolute error vs. ISO 19344. Horizon Europe consortia. In discussion with Japanese pharma, diagnostics and food companies.



REMANALYTICS

STAGE
Revenue-stage —
Series A

CURRENT TARGET RAISE
JPY 380 million

WANTED Japanese partners who hold a biomarker, a strain or a health claim and need it measured, proven and registered: pharma, diagnostics and food companies for co-development; laboratories, CROs and distributors to place our instrument and run our assays in Japan. Investors for our Series A. I am in Tokyo in October and would be glad to meet in person.





ELISABETH
BRUNNER // CEO



WEBSITE

<https://thyra-imaging.com>

**DATE OF
INCORPORATION**
03/2026

SECTOR

MedTech // Medical
Imaging // AI
// Neuroscience
// Aging & Longevity
// DeepTech

SPEAKER

Elisabeth
Brunner // CEO

CONTACT

✉ elisabeth.brunner@thyra-imaging.com

COMPANY

Thyra Imaging
FlexCo

STAGE

Pre-Seed

WANTED

Investors (Family Offices, Business Angels, Venture Capitalists) // Manufacturers // Clinical Research Institutions // Pharmaceutical Companies // Contract Research Organizations // Distributors

CURRENT TARGET RAISE
EUR >500K



PRODUCT/SERVICE

NEUROINFLAMMATION IS A KEY DRIVER IN NEURODEGENERATIVE DISEASES like Alzheimer's disease. Understanding neuroinflammation is key to develop better treatments that act before cognitive symptoms occur. Until now, we have been lacking good tools to do that. Thyra Imaging has developed the first non-invasive technology to assess neuroinflammation through high resolution imaging of microglia immune cells in the retina, which is known to mirror brain health.

CORE CAPABILITIES TECHNOLOGY & COMPETITIVE EDGE

We have developed the only technology that can non-invasively image microglia immune cell activation in the retina, combining adaptive optics from astronomy with optical coherence tomography from ophthalmology. Developed in the clinic, our laboratory prototype has already been used on actual patients, generating proprietary insights for our future commercial product and datasets to develop AI-assisted software enabling future use by non-specialist clinicians.

PERFORMANCE & TRACTION

- ✓ Secured 300,000EUR non-dilutive Pre-Seed funding
- ✓ Co-Founders named "Inventors of the Year 2025" by the Medical University of Vienna
- ✓ Signed data transfer agreement with Medical University of Vienna to access past and future clinical data to support product development
- ✓ Secured first investment with tech investor for Bridge round of min. 0.5M EUR to support device scale-down, AI model development and preparation for our 2-4M EUR Seed round.

TECH
BIZ
KON

Life
TECH
+

INNOVATIONS
FOR A
BETTER
LIFE

HALF TIME
BREAK
until 17:35 h



NOTES & THOUGHTS

.....

.....

.....

.....

.....


.....

.....

.....

.....

.....



PIET JAMAELS
// HEAD OF BD



COMPANY

Lysantum / brand hosted within Belgian Red Cross

DATE OF INCORPORATION
01/2026

WEBSITE

www.lysantum.com

SECTOR

Regenerative medicine // cell & gene therapy supply // GMP raw materials

TEAM

- Philippe Vandekerckhove // CEO, Belg. Red Cr. Flanders
- Piet Jamaels // Head of BD

CONTACT

e piet.jamaels@rodekruis.be
sales.hpl@rodekruis.be

STAGE

Lysantum start up incubating within Belgian Red Cross

WANTED

- Parties interested in taking a license on our patented & scalable Lysantum technology to produce hPL from platelets.

CURRENT TARGET RAISE
not raising

- Connect us with cell therapy developers & manufacturers who need hPL for cell & tissue culture

- Connect us with cell culture media distributors active in Japan



PRODUCT/SERVICE

LYSANTUM IS A GMP-GRADE, XENO-FREE HUMAN PLATELET LYSATE (HPL) developed by Belgian Red Cross, replacing FBS in cell therapy and regenerative medicine. Sourced from voluntary European donors with pathogen inactivation, it's the only HPL backed by a blood establishment that both makes and sells it, ensuring donor-to-vial traceability. Available as Premium and Ultra lines, in Research and Clinical grades.

CORE CAPABILITIES TECHNOLOGY & COMPETITIVE EDGE

- Reliable & scaleable supply
- Patented technology
- Closed system production
- Low batch to batch variability
- Pathogen Inactivated
- European voluntary donors
- 100% donor to vial traceability
- Eu SoHo compliant

PERFORMANCE & TRACTION

- 5 peer review publications referencing Lysantum HPL
- 4 established distributors in Europe
- 1 established distributor for mainland China & Taiwan
- Multiple parties interested in licencing the technology (US, Europe, China)



MASAKI
TAKEUCHI // CEO



COMPANY

Corroquium Inc.

SPEAKER

Masaki Takeuchi, Ph.D.
// Founder & CEO

SECTOR

Assistive Technology // HealthTech // Wearable Devices

DATE OF INCORP.

04/2025

WEBSITE

https://corroquium.com

CONTACT

e masaki.takeuchi@corroquium.com
m +81 80 5547 7728

STAGE

Early commercial stage // Made-to-order production

CURRENT TARGET RAISE

JPY TBD // open to strategic investment discussions

WANTED

We seek strategic investors and partners to accelerate product engineering, quality assurance and scalable manufacturing. We also welcome hospitals, clinicians, patient organisations, overseas distributors and regulatory partners for clinical validation, market entry and global distribution, beginning with the US and Asia.



PRODUCT/SERVICE


LARYPHONIX IS A HANDS-FREE WEARABLE ELECTROLARYNX for people who cannot generate voice with their vocal cords after laryngectomy, tracheotomy or other conditions. Worn around the neck, it transmits vibration through the skin so users can articulate speech without holding a device. It is custom-fitted, volume-adjustable and designed to reproduce a more natural, personalised voice using the user's voice data.

CORE CAPABILITIES TECHNOLOGY & COMPETITIVE EDGE

Five years of user-centred R&D combine neck-worn hardware, acoustic/vibration tuning and personalised source-sound generation. Unlike conventional handheld electrolarynges, Laryphonix enables hands-free conversation, individual fitting and a discreet, customisable design.

PERFORMANCE & TRACTION

Incorporated and launched pre-orders in 2025 with an initial 58-unit limited release at JPY 150,000 (excl. tax). Selected for Japan's FY2025 ICT Startup League. Devices are being produced sequentially with monthly customer feedback, and overseas sales are targeted within three years.



ABS
Biotechnologies



CHUKWUMA
AGU // CEO



STAGE
Seed

CURRENT TARGET RAISE
EUR 1 Mio.

WANTED
Investors // Potential Customers //
Business Partners

COMPANY
ABS Biotechnologies
GmbH

WEBSITE
<https://absbiotechnologies.com>

SPEAKER
Chukwuma Agu // CEO

DATE OF INCORP.
01/2022

SECTOR
Biotechnology

CONTACT
e chukwuma.agu
@absbiotechnologies.com

PRODUCT/SERVICE

ABS BIOTECHNOLOGIES PROVIDES A CELL-BASED PLATFORM transforming drug toxicology and development. Using iPSC-derived vascular and cardiac cells, we deliver physiologically relevant, human-based assays that improve predictability and reduce drug failure. Our automated, imaging-enabled system provides real-time insights and customizable screening solutions. By streamlining workflows, we help biotech and pharma partners accelerate drug development and improve clinical outcomes.

CORE CAPABILITIES TECHNOLOGY & COMPETITIVE EDGE

ABS Biotechnologies offers the world's first iPSC-based, organ-specific vascular models featuring neural crest-, lateral-, and paraxial mesoderm-derived smooth muscle cells, delivering unmatched vascular diversity and biological relevance. Combined with cardiomyocytes and epicardial cells, our platform enables predictive toxicology and drug discovery. Automation-ready, customizable assays provide faster, more reliable paths to clinical success.

PERFORMANCE & TRACTION

ABS Biotechnologies has already secured early commercial revenue and is building a strong pipeline of opportunities. We've established partnerships with leading industry players and top-tier academic institutions. Our proprietary platform offers validated iPSC-derived vascular and cardiac assays, supported by exclusive IP. EUR 770K in non-dilutive funding secured; now raising a seed round to unlock matching funds and accelerate scale-up and commercialization.

TECHBIZKON
10
PITCH TIME
17:47-17:52 h



VINCENT
JAENEN
// BD LEAD



SwiftPharma.

COMPANY
Swiftpharma BV

DATE OF INCORP.
02/2022

SECTOR
Biotechnology

WEBSITE
www.swiftpharma.eu

TEAM
► Jeroen Hofenk // CEO
► Vincent Jaenen, PhD
// GS, BD Lead & Speaker

CONTACT
e vincent@swiftpharma.eu
t :+324 70 70 6614

STAGE
Commercialization

CURRENT TARGET RAISE

WANTED Swiftpharma is building a portfolio of high-value recombinant proteins, custom solutions and strategic collaborations. We seek partnerships in Japan with biotechnology and pharmaceutical companies, distributors, research organizations and other life-science partners interested in innovative protein solutions and plant-based biomanufacturing.

TECHBIZKON
11
PITCH TIME
17:53-17:58 h

PRODUCT/SERVICE


FROM PROOF OF CONCEPT TO PRODUCTION AT SCALE, Swiftpharma develops animal-free recombinant proteins using plants as bio-reactors. We offer catalog proteins and custom solutions, from growth factors and mRNA enzymes to collagen-based applications. We work closely with customers to optimize production at every scale, serving cell and gene therapy, advanced cell culture, stem cells, organoids, regenerative medicine, biomaterials and selected cosmetics.

CORE CAPABILITIES TECHNOLOGY & COMPETITIVE EDGE

Swiftpharma's HyperXpress® platform uses plants to produce recombinant proteins through rapid transient expression and optimized purification. It enables flexible, scalable and animal-free production of complex proteins, offering an alternative to conventional microbial and mammalian-cell systems.

PERFORMANCE & TRACTION

Swiftpharma is commercialized and ready to sell, with validated products and meaningful collaborations across EMEA. We are building a production facility to scale volumes, while engaging OEMs, distributors and validation labs. We plan an ambitious go-to-market by year-end.



HENRY STEHLE
// CEO



COMPANY

Aortex

DATE OF INCORP.

07/2024

SECTOR

Medtech // Medical Devices

WEBSITE

<https://aortex.eu>

TEAM

- ✓ Henry Stehle // CEO & Speaker
- ✓ Maximilian Dunker // CTO

CONTACT

e henry.stehle@aortex.eu
m +49 176 3454 6911



PRODUCT/SERVICE

AORTEX DEVELOPS AN AORTIC PROTHESIS, for aneurysms which enables safer, faster, and customized treatment. Up to 30–50% of patients cannot receive EVAR due to small or complex access vessels, that lead to life-threatening complications. Therefore, Aortex provides a mass-customized stent graft in hours instead of months, enabling urgent, anatomy-accurate treatment. Those stent grafts fit in 20% smaller catheters than today's products at much lower price.

CORE CAPABILITIES

TECHNOLOGY & COMPETITIVE EDGE

- ✓ 50% smaller and ultra strong textile that can be used for a variety of medical textile applications.
- ✓ Mass-customization based on patients' aorta 3D CT scan including fenestrations and branches.
- ✓ One-step combination of stent and graft avoiding manual sewing processes.
- ✓ Avoidance of forever chemicals.

PERFORMANCE & TRACTION

- ✓ 100M JPY (500k€) already raised
- ✓ Product and manufacturing process patented, next patents in application
- ✓ Prototype built and tested with outstanding results
- ✓ Collaborations with global Medtech companies, material & machinery supplier universities and experts in cardiovascular and technology science.



ANDREA CHICCA
// CO-FNDR. & CEO

COMPANY

Synendos
Therapeutics AG

DATE OF INCORP.

04/2019

SECTOR

Biotech // Neuroscience

WEBSITE


www.synendos.com

TEAM

- ✓ Andrea Chicca // Co-founder & CEO
- ✓ Simon Russell // Co-founder & CCO

CONTACT

e andrea.chicca@synendos.com



STAGE

Phase 2
Clinical Stage

CURRENT TARGET RAISE

Up to CHF 50M
Series B

WANTED

We seek Japanese pharmaceutical licensing/co-development partners and investors for SYT-510. Priorities are to validate the partnering proposition, build relationships with neuroscience-focused pharma, and support a Series B of up to CHF 50M as the Phase 2 program progresses.

PRODUCT/SERVICE

SYNENDOS DEVELOPS NOVEL SMALL-MOLECULE THERAPIES for neuropsychiatric and neurological disorders. Lead candidate SYT-510 is a first-in-class Selective Endocannabinoid Re-uptake Inhibitor (SERI) designed to modulate the endocannabinoid system and restore healthy neurotransmitter balance. A Phase 2 proof-of-concept study is underway in Generalized Anxiety Disorder.




CORE CAPABILITIES

TECHNOLOGY & COMPETITIVE EDGE

First-in-class SERI platform targeting the endocannabinoid system through a self-limiting mode of action. SYT-510 is protected by composition-of-matter and medical-use IP in the US, EU, Japan and other major territories, with additional patents being filed.

PERFORMANCE & TRACTION

Phase 1 completed with excellent safety and exposure results; Phase 2 PoC in GAD is underway. CHF 40M in third-party investment secured. SYT-510 has granted IP in the US, EU and Japan, and Synendos is in discussions with several multinational pharma companies.



ILIAS
ZEMPELIN
// COO



COMPANY
Cynteract

DATE OF INCORPORATION
11/2016

SECTOR
Health Tech

WEBSITE
www.cynteract.com

SPEAKER
Ilias Zempelin // COO

CONTACT
e i.zempelin@cynteract.com

STAGE
Growth

CURRENT TARGET RAISE

WANTED
We aim to connect with medical distributors to scale our market presence in Japan, and collaborate with healthcare partners to better understand local customer needs.

PRODUCT/SERVICE

CYNTERACT MAKES HAND REHABILITATION ENGAGING AND DIGITAL.

We develop smart, sensor-based rehab gloves that turn tedious exercises after strokes, injuries, or surgeries into interactive video games. Patients can train gamified at home or in the clinic, while therapists accurately track their precise healing progress digitally.

CORE CAPABILITIES
TECHNOLOGY & COMPETITIVE EDGE


Smart, sensor-based rehab gloves for gamified hand therapy. We turn repetitive exercises after strokes or injuries into engaging video games, running natively on smartphones and tablets while measuring real-time biomechanical progress for clinicians.

PERFORMANCE & TRACTION

Certified medical device successfully entering European B2C and B2B markets. Scalable Go-To-Market strategy with active distribution rollouts in the Benelux region, Australia, and upcoming expansion into Japan. Proven clinical usability and high patient engagement in home rehabilitation.



YUJI OTSUKI
// CEO



COMPANY

FerroptoCure Inc.

DATE OF INCORP.
05/2026

SECTOR
Biotech // Pharmaceutical

WEBSITE

https://ferroptocure.com

SPEAKER

Yuji Otsuki // CEO

CONTACT

e yotsuki@ferroptocure.com

STAGE
Series A

CRNT.TGT.RS.
JPY 1,030,000,000



WANTED

We seek European pharmaceutical partners for licensing and co-development, especially companies with strong oncology development and commercialization capabilities in the EU. We also welcome European investors and clinical/translational partners who can support biomarker-driven development and future EU clinical expansion.

PRODUCT/SERVICE

FERROPTOCURE DEVELOPS FIRST-IN-CLASS ORAL SMALL-MOLECULE THERAPIES that induce ferroptosis, a distinct form of cell death driven by lethal lipid peroxidation. Because many refractory cancers evade conventional apoptosis-based treatments, ferroptosis offers an alternative way to eliminate drug-resistant tumor cells. We aim to establish a new treatment option across multiple solid tumors.

CORE CAPABILITIES
TECHNOLOGY & COMP. EDGE

Our core capability is dual targeting of xCT and ALDH, two complementary antioxidant defenses in cancer. By inhibiting both pathways in a single oral small molecule, we drive ferroptosis more effectively, creating a differentiated strategy to overcome drug resistance.

PERFORMANCE & TRACTION

Keio University School of Medicine spin-out founded in 2022. Our lead program has reached Phase I clinical evaluation. We completed Series A financing, secured major AMED support, established an Australian subsidiary, and are advancing global development, including future expansion into Europe.

FURTHER STARTUPS
EXHIBITING ONLY

The startups featured on the following pages are not pitching at the event onsite. However, they will be available for talks during networking time at their exhibiting tables and online.



TABLE 16

MEDTECH // FEMTECH // LONGEVITY
// PREVENTIVE HEALTH

Alitheo Biotechnology GmbH
<https://alitheo-bio.com>



Fanny Giannou // Founder & CEO
fanny.giannou@alitheo-bio.com

Alitheo Bio is a biotech company developing next-generation technologies for personalized cancer immunotherapy. Our immuno-peptidomics platform enables rapid, efficient identification of peptides presented by human cells, accelerating biomarker discovery and therapeutic target development.

CheckImmune

TABLE 17

MEDTECH // BIOMARKERS //
PERSONALIZED MEDICINE

CheckImmune GmbH
www.checkimmune.com



Dr. Andreas Hüser // CEO
andreas.hueser@checkimmune.com

CheckImmune is an accredited Berlin-based immune biomarker CRO and scientific development partner supporting preclinical and clinical drug development. Working closely with sponsors, we provide end-to-end expertise, from biomarker strategy and assay development to GCLP-compliant immune monitoring and data interpretation.



TABLE 18

MEDTECH DEVICE // DIAGNOSTICS

Curio Biotech
www.curio-biotech.com
Dr. Chennakesava Cuddapah
// Founder & CEO
cuddapah@curio-biotech.com



Founded in 2017, Curio Biotech is a Swiss in vitro CRO specializing in human-relevant cell and tissue systems for drug discovery, efficacy and safety testing. Its Colentes brand provides specialized cell culture media and solutions for primary cells, bioassays, tissue engineering and cell therapies, advancing NAMs and 3R-aligned research.



TABLE 20

CELL & GENE THERAPY //
BIOPROCESSING

FyonBio GmbH
www.fyonbio.com



Lars Stoeckel // Managing Director
lars.stoeckel@fyonbio.com

FyonBio is a Berlin-based biotech service provider specializing in cell line development for biologics. Its proprietary CHOnamite®, CHOFlow® and GlycoExpress® platforms are complemented by advanced CMC analytics, mass spectrometry and tailored PK, PD, ADA and biomarker assays to support biopharmaceutical development from early-stage research through clinical programs.



TABLE 19

FEMTECH // DIAGNOSTICS

Diamens FlexCo
<https://diamens.org>



Angelika Lackner // CSO
angelika@diamens.org

Non-invasive diagnostic test to detect endometriosis: self-administered, discreet and without pain.



TABLE 21

MEDTECH // IMMUNE BIOMARKERS //
WELLNESS // DIGITAL HEALTH

Immunosens Co., Ltd.
<https://immunosens.com>



Hirokazu Sugihara // Founder & CEO
h-sugihara@immunosens.com

IMMUNOSENS, spun out from the University of Osaka, has built GLEIA, a palm-sized quantitative immunoassay platform starting with cardiovascular care. With its reader notified and assays certified in Japan, it delivers 1 pg/mL sensitivity in 5-10 minutes at ~1/1,000 the price of large analyzers, supporting clinics and physician-guided home monitoring.



TABLE 22

BIOTECHNOLOGY // PHARMA R&D // ADVANCED THERAPEUTIC

KinCon biolabs
www.kincon-biolabs.euEduard Stefan // CEO
eduard.stefan@kincon-biolabs.eu

Empowering discovery and selection of the most potent drug candidates for hard-to-target proteins.

Japan is now associated with Horizon Europe's €93.5bn research programme, creating new opportunities for EU-Japan collaboration in health, biotechnology and innovation.

European Commission
<https://research-and-innovation.ec.europa.eu>

TABLE 23

DEVICE // FEMTECH // LONGEVITY // WELLNESS & PREVENTIVE HEALTH

Luminous Labs FlexCo
www.luminouslabs.healthBarbara Sekulovska // CEO
hello@luminouslabs.health

Luminous Labs develops photobiomodulation technology for female longevity, combining red/NIR light with proprietary spectral and dosing technologies for wellness, research and premium B2B longevity experiences.



TABLE 24

REHAB DEVICE // MED TECH // WEARABLES

Magnes
<https://magnes.ch>Dr. Olgac Ergeneman // Co-Founder & CEO
oergeneman@magnes.ch

Magnes is a Swiss medtech company spun out of ETH Zurich. We develop AI-powered wearables that analyze movement and provide real-time vibrotactile feedback. Our flagship NUSHU smart shoe supports gait assessment, stability, and personalized rehabilitation for people with neurological and movement disorders.



TABLE 25

BIOTECHNOLOGY // PHARMA R&D // ADVANCED THERAPEUTIC

Nanotis
<http://nanotis.net>Naoko Kita // Corporate Strategy Director
kita@nanotis.net

Nanotis is a Japanese healthtech startup developing a rapid diagnostic platform for infectious diseases. Using proprietary dielectrophoretic concentration technology, Nanotis aims to deliver reliable results from saliva in just three minutes. Its mission is to make infectious disease testing faster, simpler, more accessible, and digitally connected.



TABLE 26

NEUROLONIC

DIGITAL HEALTH // MEDICAL DEVICE // WEARABLES

NeuroLonic UG
www.neurolonic.com
Thiruvikkiraman Pandurangan
// Co-Founder & CEO
vikki@neurolonic.com

NeuroLonic is a Berlin-based AI technology company developing voice-based emotional intelligence and mental-wellness solutions. Our technology analyses vocal characteristics and emotional patterns to provide accessible, privacy-conscious digital support for mental well-being and healthcare applications.

Enterprise Europe Network (EEN) Gateway between Europe and Japan



The world's largest support network for small and medium-sized enterprises (SMEs) with international ambitions. Active in more than 60 countries worldwide including Japan.



Business Support on Your Doorstep

Find

- ☐ Partners for developing sales channels in Europe
- ☐ Innovative European products or technologies to boost your business development
- ☐ Partners for joint research and development
- ☐ Information on European companies and research organisations

More details:
<https://www.eu-japan.eu/een>

Interested?
Contact EEN Japan
at the
EU-Japan Centre
for Industrial
Cooperation



MEDTECH // MED. DEVICES // ENDO-
SCOPY // ENDOSCOPIC ROBOTICS

NGScopes
<https://ngscopes.com>



Sascha Bruk // Head of PM & Co-Founder
Sascha.Bruk@ngscopes.com

NGScopes is a preclinical medical device startup developing retrofit, through-the-scope robotic instruments for endoscopy, with the lead product an electrosurgical knife for advanced endoscopic resection. Our instruments seamlessly integrate robotic precision into the existing single-operator workflow, preserving physicians' existing skill sets and installed infrastructure.

BIOTECH // PHARMA R&D // FOOD-
TECH (CELLULAR AGRICULTURE)

Nuvonis Technologies GmbH
<https://nuvonis.com>



Andreas Aspoeck // Director MSAT
a.aspoeck@nuvonis.com

We develop and provide innovative GMP cell bank systems. Our cell lines are used to manufacture vaccines for human and animal health, as well as cultivated meat for the novel food sector.

Japan's association with Horizon Europe will strengthen international research collaboration and Japan's science and technology capabilities.

Ministry of Foreign Affairs of Japan (MOFA), 2026
Horizon Europe Agreement
www.mofa.go.jp



TECHBIO // BIOINFORMATICS //
AI AGENTS // RNA-SEQ

OmicsBuddy
www.omicsbuddy.com



Thomas Ulas // CSO & Co-Founder
t.ulas@uni-bonn.de

OMICSBuddy develops an AI-powered bioinformatics platform for RNA-seq and transcriptomics analysis. Its agentic AI workflow guides researchers through quality control, differential expression, machine learning and biological interpretation, helping scientists generate actionable hypotheses without extensive coding while keeping sensitive data within their own infrastructure.

LONGEVITY & REGENERATIVE MED. //
WELLNESS & PREVENTIVE HEALTH

OrganTech Inc
www.organ-tech.jp/en



Yoshitake Yamaguchi Ph.D. // Rep. Dir. & COO
yoshitake.yamaguchi@organ-tech.jp

OrganTech is a biotech company at the forefront of organ regeneration technologies, with innovations in dental care, hair regeneration, and artificial skin. Our novel dental implant system, the Bio-hybrid Tooth, incorporates a periodontal ligament and reproduces the biological structure and physiological functions of a natural tooth.

MEDTECH DEVICE //
DIAGNOSTICS

PRIMA genetics
<https://prima-genetics.com>



Misako Yamazaki // Project Lead & Founder
misako.yasunagayamazaki@uzh.ch

Personalised medicine depends on timely genetic information, but current genetic testing workflows are often too slow for time-sensitive clinical decisions. We are providing necessary genetic information to realise personalised medicine.

Osaka Life Science Nexus | O-Nexus



Opened May 28, 2026
Born from a joint project by **Nippon Life** and **CIC**, a life science-focused innovation hub opens at Nakanoshima Qross!

CIC is a world-class innovation campus offering a powerful community to accelerate startup growth, flexible office spaces, and a global network. Building on 10 locations worldwide, including Tokyo and Fukuoka, CIC opened its 11th campus—dedicated to life sciences—in May 2026.

CIC offers a wide range of office solutions—new headquarters, satellite offices, and spaces for hybrid teams to gather in person—tailored to each company's needs and growth stage. More than just office space, O-Nexus is built to be a place where promising startups gather, get the support they need when they need it, and drive innovation in a mutually beneficial environment.



A launchpad for innovation where you can focus on your work.
Located on floors 8 & 9 of Nakanoshima Qross (approx. 3,100 m²).
Space highlights:

123

Private offices for 1-15 people

25

Co-working desks open, comfortable environment

14

Meeting rooms bookable online

13

Phone booths including wheelchair accessible booths

Focus on your business in an all-inclusive environment

All services below are included in your monthly fee—no extra charges.

- * Fully furnished
- * Move-in ready
- * just bring your laptop
- * Connect with members at other locations anytime, online
- * Change or move out with 30 days' notice
- * Access to domestic & global locations (conditions apply)

Included Amenities

- Meeting rooms
- Video conference rooms
- Soundproof phone booths
- Well-stocked kitchen
- 24/7 access
- Bilingual support (JP/EN)
- High-speed internet
- Registered business address
- Dedicated phone number (06)
- Copying & printing
- CIC Global Passport

QFF

TABLE 32

AGRITECH & DEEP TECH //
WELLNESS & PREVENTIVE HEALTHQuantum Flowers & Foods Co., Ltd.
<https://qff.jp/en>Shunsuke Naito // CMO & Sales Manager
shunsuke.naito@qff.jp

Quantum Flowers & Foods (QFF) accelerates the development of plants and microorganisms using its proprietary neutron irradiation technology. Our non-GMO breeding solutions generate diverse genetic variations, helping partners create improved strains and varieties faster for agriculture, food, and biotechnology applications.

Japan's life sciences market includes a USD 78bn pharmaceutical market and a USD 28.7bn medical device market, with digital health and regenerative medicine among key growth areas

Japan External
Trade Organization
www.jetro.go.jp



TABLE 33

APP // E-HEALTH //
MEDICAL DEVICE // LIFESTYLESnore Free
<https://snorefree.com>Sigismund Kremser // CEO
office@snorefree.com

We are a medically certified healthcare app that tackles the root causes of snoring and sleep apnea through simple oral training – anytime, anywhere.



TABLE 34

MENTAL HEALTH // VOICE AI //
STRESS PREVENTION // WELLBEINGSymind
<https://symind.de>Serhiy Danilevych // Founder & Engineer
serhiy@symind.de

Symind is a voice-first AI assistant that identifies and interrupts overthinking loops in real time. By catching spiraling thoughts before they escalate, we support mental well-being and help prevent the toll that chronic stress and rumination take over time



TABLE 35

MEDTECH & ASSISTIVE TECH //
WELLNESS & PREVENTIVE HEALTHThe Elements, Inc.
<https://the-elements.jp/en>Tomofumi Fukamiya // Founder & CEO
fukamiya@the-elements.jp

The Elements builds the market infrastructure for assistive technology (AT): applying health technology assessment to prove AT's value, then connecting suppliers and demand across Japan, India, and Europe. We turn promising AT into a sustainable market for aging and disabled populations.



TABLE 36

DIGITAL HEALTH & ASSISTIVE TECH //
DEEP TECH & METAVERSE

toraru co.,ltd.
www.toraru.me/en
Jun Nishiguchi // Founder & CEO
Megumi Iriya // Co-founder & COO
megumi@toraru.co.jp



GENCHI is a semi-teleportation platform enabling remote, immersive experiences in Japan through local human support, sight, sound, and touch. It provides equal access and personalized exploration, promoting accessibility, social inclusion, and enhanced quality of life for individuals with disabilities or mobility barriers.

Austria is scaling up as a Life sciences location

MedUni Vienna is expanding one of Europe's leading medical research environments: together with Vienna General Hospital, one of the world's largest hospitals, it combines top-level clinical practice with research excellence and ranks among the global top 20 in clinical and health sciences. Two new research buildings opening in autumn 2026 will further strengthen translational and precision medicine and bring research, clinics and industry even closer together.

Across Austria, more than 1,170 life science companies employ around 73,400 people and generate nearly €40 billion in revenue. The Industrial Strategy 2035 identifies life sciences and biotechnology

as key technologies for competitiveness and resilience. Global players such as MSD, Takeda, Boehringer Ingelheim and GE HealthCare use Austria for research, manufacturing and clinical innovation.

Good reasons to select Austria

14% research tax credit

- Combines direct/indirect funding programs.
- You receive 14% of all your research expenditures as a cash payment – regardless of your firm's size, sector and corporate structure.



© Cavan
Images/
Westend63

Austria's national investment promotion agency ABA

is happy to support you in establishing business operations in Austria – cost-free and confidential!

Contact: Matthias Adelwoehrer, Director Asia, INVEST in AUSTRIA
m.adelwoehrer@aba.gv.at | www.investinaustria.at/jp/

ABA INVEST
WORK
FILM
Your easy access to Austria



HISTORY

Since 2017, TechBIZKON successfully connects startups, corporates and investors. Find out more on www.techbizkon.com/past-editions.html



2017 The Beginning For the first edition we had Q1-Booster as accelerator and Japanese partner and the New York Univ. campus in Shinagawa as venue partner.



2020 Connected Industries This was all about the tech and solutions making smart factories, well, smart. This edition had two Japanese partners, CIC and Venture Cafe. It was also our most affected by the pandemic.



2023 Microelectronics More than 30 startups focused on microelectronic and semiconductors participated in the 7th edition at QWS Shibuya, December 12th, 2023.



2018 Artificial Intelligence Seven startups from Austria, Germany and Switzerland were joined by four startups from Japan from where CREWW had joined as the Japanese partner.



2021 Greentech In the center of Tokyo's startup world right at Shibuya crossing, this edition focused on THE topic of our time - greentech, sustainability and saving the planet for our children and generations to come.



2024 AgriTech & Food Tech Solutions and ideas to problems in agriculture, the food industry and similar areas were presented by more than 30 startups in front of an audience of roughly 200 B2B industry contacts.



2019 Digital Health Nobody knew how timely the topic for the TechBIZKON 2019 was chosen. Our third edition took place just before the world faced the Covid-19 crisis.



2022 Mobility With Toyota Connected, the open innovation company of Toyota Group, we had a total of 30 participating startups, 15 pitching, 15 exhibiting.



2025 GX FactoryTech More than 20 startups showcased how industry and manufacturing can go green to contribute to a sustainable future. Industry professionals, investors & corporate representatives joined at Inspired.Lab@SAP.

Friday, October 9th, 2026
1:15 pm to 8:40pm, door: 12:45 pm
Tokyo Innovation Base //
Yurakucho // & online

TechBIZKON X
Connecting
Startups, Corporates & Investors



ORGANIZERS

AUSTRIA



ADVANTAGE AUSTRIA TOKYO
www.advantageaustria.org
3-13-3 Motoazabu
Minato-ku, Tokyo
T +81 3 3403 1777,
E tokyo@advantageaustria.org

BELGIUM



FLANDERS INVESTMENT & TRADE TOKYO
<https://flandersinvestmentandtrade.com>
c/o Embassy of Belgium
5-4 Nibancho
Chiyoda-ku, Tokyo
T +81-3-5210-5884
E tokyo@fitagency.com

GERMANY



GERMAN CHAMBER OF COMMERCE AND INDUSTRY IN JAPAN
<https://japan.ahk.de/en>
Sanbancho KS Bldg. 5F
2-4 Sanbancho
Chiyoda-ku, Tokyo
T +81 3 5276 8829,
E techbizkon@dihkj.or.jp

JAPAN



PLUG AND PLAY
<https://japan.pluginplaytechcenter.com>
150-0043 Tokyo
Shibuya City, Dogenzaka
1 Chome-16-3 3F

SWITZERLAND



SWISSNEX IN JAPAN
<https://swissnex.org/japan>
Umeda Shinmichi Bldg. 1F
1-1-5 Dojima, Kita-ku
Osaka 530-0003
T +81 6 7777 2546
E japan@swissnex.org

CO-ORGANIZERS



GERMAN CENTER FOR RESEARCH AND INNOVATION (DWIH)
www.dwih-tokyo.org



EU-JAPAN CENTRE FOR INDUSTRIAL COOPERATION
www.eu-japan.eu

LifeTECH+
INNOVATIONS FOR A BETTER LIFE

T O K Y O
O C T 9TH
2 0 2 6

TechBIZKON X SPONSORS

DIAMOND

www.ucbjapan.com



Inspired by **patients**.
Driven by **science**.

PLATINUM

www.o-nexus.jp



www.gin-austria.com/landingpage/japan



aba.gv.at/en



SILVER

www.redbull.com/jp-ja



<https://zeroproject.org>



TechBIZKON X SUPPORTERS

<https://ascii.jp/startup>



www.joi.or.jp/en




<https://cariso-su.mhlw.go.jp>



<https://mediso.mhlw.go.jp>



www.go-international.at



www.english.metro.tokyo.lg.jp



<https://jane.or.jp>



<https://sccij.jp>

